Fast Five: Baxter considers Kidney Care sale, Medtronic earns FDA nod for ablation tech
Update: 2024-03-05
Description
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, March 5, 2024.
Check out the show notes at MassDevice.com/podcast.
The FDA approved Boston Scientific’s Agent drug-coated balloon. Fast Five hosts Chris Newmarker and Sean Whooley explain the significance of this approval and dive into why analysts think it's a major win for Boston Scientific.
BD has initiated a new trial for its Vascular Covered Stent. Find out more about what the stent does and why BD thinks it addresses a significant unmet need.
Phagenesis reportedly brought in $42 million in funding for its neurostimulation technology. The hosts take a look at what the technology actually is and what the British medtech company plans to do with its latest cash influx.
Medtronic picked up FDA clearance for its latest-generation bone tumor ablation technology. Hear all about what sets this technology apart from the competition and from Medtronic's previous bone ablation system.
Baxter has a major update on its planned Kidney Care spinoff. The Fast Five hosts break down a bit of a twist in Baxter's separation plans and discuss how it folds into a recent trend across the medtech space.
Check out the show notes at MassDevice.com/podcast.
The FDA approved Boston Scientific’s Agent drug-coated balloon. Fast Five hosts Chris Newmarker and Sean Whooley explain the significance of this approval and dive into why analysts think it's a major win for Boston Scientific.
BD has initiated a new trial for its Vascular Covered Stent. Find out more about what the stent does and why BD thinks it addresses a significant unmet need.
Phagenesis reportedly brought in $42 million in funding for its neurostimulation technology. The hosts take a look at what the technology actually is and what the British medtech company plans to do with its latest cash influx.
Medtronic picked up FDA clearance for its latest-generation bone tumor ablation technology. Hear all about what sets this technology apart from the competition and from Medtronic's previous bone ablation system.
Baxter has a major update on its planned Kidney Care spinoff. The Fast Five hosts break down a bit of a twist in Baxter's separation plans and discuss how it folds into a recent trend across the medtech space.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
